"This is the best international plane ever built yet -- it's got an impeccable track record after 20 years and over 1,200 deliveries," said Richard Aboulafia, vice president for analysis with the Teal Group in Virginia. "It's typically used on international routes and it's established a new standard for international safety."
The crash in the South China Sea with 239 people aboard is Malaysia Airlines' first crash in nearly 20 years.
The Asiana Airlines Flight 214 crash that killed three people last July also involved a 777, which struck a seawall and broke apart at San Francisco's airport. But National Transportation Safety Board investigators have focused their attention on pilot training and confusion in that incident.
Top Mid Cap Companies To Invest In 2015: Eastman Chemical Company (EMN)
Eastman Chemical Company, a chemical company, engages in the manufacture and sale of chemicals, plastics, and fibers in the United States and internationally. The company operates in four segments: Coatings, Adhesives, Specialty Polymers, and Inks (CASPI); Fibers; Performance Chemicals and Intermediates (PCI); and Specialty Plastics. The CASPI segment manufactures resins, specialty polymers, and solvents that are used in the production of paints and coatings, inks, adhesives, and other formulated products. The Fibers segment offers Estron acetate tow and Estrobond triacetin plasticizers used in cigarette filters; Estron natural and Chromspun solution-dyed acetate yarns for use in apparel, home furnishings, and industrial fabrics; and cellulose acetate flake and acetyl raw materials for acetate fiber producers. The PCI segment offers intermediates; performance chemicals; and complex organic molecules, such as diketene derivatives, specialty ketones, and specialty anhydrides for medical, pharmaceutical, fiber, and food and beverage ingredients, which are used in specialty market applications. This segment?s products are used in various markets and end uses, including agriculture, transportation, beverages, nutrition, pharmaceuticals, coatings, medical devices, toys, adhesives, household products, polymers, textiles, and consumer and industrial products, as well as used for health and wellness uses. The Specialty Plastics segment primarily offers engineering and specialty polymers, specialty film and sheet products, and packaging film and fiber products. This segment?s products include specialty copolyesters and cellulosic plastics, which are used in specialty packaging, in-store fixtures and displays, consumer and durable goods, medical goods, personal care and consumer packaging, photographic film, optical film, fibers/nonwovens, tapes/labels, and LCD?s. The company was founded in 1920 and is headquartered in Kingsport, Tennessee.
Advisors' Opinion:- [By Monica Gerson]
Eastman Chemical Co (NYSE: EMN) is expected to post its Q3 earnings at $1.64 per share on revenue of $2.34 billion.
Potash Corp. of Saskatchewan (NYSE: POT) is projected to report its Q3 earnings at $0.43 per share on revenue of $1.53 billion.
- [By Victor Selva] e exception. The firm has made an emphasis on its acetate tow production, mainly used for cigarettes. The company stands out for using coal as its input, in contrast with other competitors using petroleum and gas, both more expensive for production. This mark up has allowed Eastman to transfer some of its increasing costs onto prices, �without compromising its sales revenue.
In addition to this, the acquisition of Solutia Inc. (former global leader in performance materials) completed on July 2, 2012, broadened Eastman�� specialty chemicals output by adding automotive and solar end products to its portfolio.
Although Eastman is a highly diversified company, it has proven to be severely affected by negative cycles of the economy. Even though this feature is not appealing whatsoever to investments, it certainly has caused it to become a cheap alternative. And, a quite promising one, since the economic recovery boosted its revenue, as a result of Eastman�� focus on cost-advantage production methods.
Other specialty chemical competitors, such as Ashland Incorporated (ASH) didn�� show such a promising comeback, and the drop in revenue during 2012 was anticipated by investor Jean-Marie Eveillard (Trades, Portfolio), who sold out his 3.9 million share position by the third quarter of that year.
Another industry giant, Huntsman Corporation (HUN) did show more promising results, and less volatile revenues during these last years. This, of course, has led to a high price to earnings ratio discouraging investors as we see later.
Geographically Diversified
On 2012, almost 50% of Eastman sales were generated in North America, while more than 25% were in Asia and 20% in Europe, Middle East and Africa. This diversification is to be taken into account since it guarantees long-term revenue, even if cigarette consumption decreases in some specific region (for instance, American sales declined �in recent years),
- [By Michael A. Robinson]
Today, Eastman Chemical Company (NYSE: EMN) ranks as an industry leader with a $12 billion market cap and whose stock is up 350% over the past five years, not counting the 1.5% dividend.
Top 10 Safest Companies To Buy For 2014: NPS Pharmaceuticals Inc.(NPSP)
NPS Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for gastrointestinal and endocrine disorders, and various medical needs. The company?s primary clinical programs include two therapeutic peptides to restore or replace biological functions comprising GATTEX, a Phase 3 clinical trial product for short bowel syndrome; and Natpara, a recombinant human parathyroid hormone 1-84, which is in Phase 3 clinical development trials. It also develops NPSP790 and NPSP795 calcilytic compounds that are in Phase I trials for the treatment of rare endocrine disorders. The company has collaborative and license agreements with Amgen Inc., Janssen, GlaxoSmithKline, Kyowa Hakko Kirin, and Nycomed Danmark ApS. NPS Pharmaceuticals, Inc. was founded in 1986 and is based in Bedminster, New Jersey.
Advisors' Opinion:- [By Louis Navellier]
SVA is a strong buy at the current price.
Biotech Stocks to Buy: NPS Pharmaceuticals (NPSP)NPS Pharmacuticals (NPSP) currently has five drugs� for things like osteoporosis, hyperparathyroidism, pain management and short bowel syndrome. They focus their research efforts right now on things like gastrointestinal, psychiatric, neurological and� bone and mineral disorders. The company had triple digit gains in sales and earnings in the most recent quarter and the strong fundamentals were noticed by Portfolio Grader.
Top 10 Safest Companies To Buy For 2014: Malvern Federal Bancorp Inc.(MLVF)
Malvern Federal Bancorp, Inc. operates as the bank holding company for Malvern Federal Savings Bank, which is a federally chartered savings bank. It provides banking services in Pennsylvania. The company engages in attracting deposits from the general public and using those funds to invest in loans and investment securities. Its deposit products include interest-bearing and non-interest-bearing checking accounts, as well as money market, savings, and certificate of deposit accounts. The company?s loan products principally include one-to four family residential mortgage loans; and consumer loans comprising home equity loans, home equity lines of credit, automobile loans, unsecured personal loans, and loans secured by deposits. It conducts business from its headquarters and eight full-service branches in Chester and Delaware Counties, Pennsylvania. The company was founded in 1887 and is headquartered in Paoli, Pennsylvania.
Advisors' Opinion:- [By Tim Melvin]
Malvern Federal (MLVF) is a great example of a small financial institution at a cheap price with a sound financial condition. The bank has 8 branches in the Chester and Delaware counties of Pennsylvania. The bank has been around since 1897 and currently has about $600 million in assets. MLVF has a great balance sheet, with an equity-to-assets ratio of 10.9 and nonperforming assets that are just 1.98% of total assets.
Top 10 Safest Companies To Buy For 2014: Infinity Pharmaceuticals Inc.(INFI)
Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for difficult-to-treat diseases. The company?s lead product candidates include saridegib (IPI-926), an oral molecule with the potential to treat a range of cancers by disrupting malignant activation of the Hedgehog pathway; and Retaspimycin HCl (IPI-504), a heat shock protein 90 (Hsp90) inhibitor. Its Saridegib is in a Phase II clinical trial for the treatment of metastatic or inoperable chondrosarcoma and a Phase II exploratory trial in patients with myelofibrosis. The company?s Retaspimycin HCl is in a Phase II trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC); and in a Phase Ib/II trial in combination with everolimus, known as Afinitor, in approximately 45 NSCLC patients with a KRAS mutation. Its pipeline also includes IPI-145, an inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) in Phase I development to treat in flammation and hematologic malignancies. Infinity Pharmaceuticals has a strategic alliance with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited to develop and commercialize pharmaceutical products; and a development and license agreement with Millennium to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K, including IPI-145. Purdue Pharmaceutical Products is planning to conduct Phase II studies of IPI-940 in pain. The company is headquartered in Cambridge, Massachusetts.
Advisors' Opinion:- [By Bryan Murphy]
When investors think of non-Hodgkin's lymphoma stocks, big names like Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG) come to mind. Both GILD and CELG are making prolific progress in the war on NHL, and both are fine, well-positioned companies. It's little Infinity Pharmaceuticals Inc. (NASDAQ:INFI) that may end up making the proverbial quantum leap in the non-Hodgkin's lymphoma stocks arena, however, and better still, it's INFI shares that may well end up doling out a much bigger reward than Gilead or Celgene could to newcomers.
- [By Luke Jacobi]
Infinity Pharmaceuticals (NASDAQ: INFI) shares shot up 44.1 percent to $15.73 on deal with AbbVie (NYSE: ABBV).
Shares of Concur Technologies (NASDAQ: CNQR) got a boost, shooting up 8.6 percent to $109.60 following a Bloomberg TV report that the company may be exploring a possible sale.
- [By Keith Speights]
No win for the spin
Another biotech, Infinity Pharmaceuticals (NASDAQ: INFI ) , also announced clinical results this week. The company's press release trumpeted "encouraging" findings for its experimental leukemia drug. Mr. Market didn't appear to buy the spin. Infinity shares tanked nearly 33% for the week.
Top 10 Safest Companies To Buy For 2014: Infoblox Inc (BLOX)
Infoblox Inc. (Infoblox), incorporated in May 2003, is an automated network controller. The Company�� network functions include Internet protocol (IP) address management, device configuration, compliance, network discovery, policy implementation, security and monitoring. The Company�� appliance-based solution combines real-time IP address management with the automation of key network control and network change and configuration management processes in purpose-built physical and virtual appliances. It is based on its software that is scalable and automates vital network functions, such as IP address management, device configuration, compliance, network discovery, policy implementation, security and monitoring. It offers two families of products: Trinzic Enterprise and Trinzic NetMRI. The Trinzic Enterprise product family enables real-time IP address management and automates key network control processes. The Trinzic NetMRI product family automates network change and configuration management processes.
Trinzic Enterprise Family
The Company derives its product revenue from its Trinzic Enterprise family of products. The components of its Trinzic Enterprise family, are Trinzic Enterprise, Trinzic IPAM for Microsoft, Trinzic Reporting and Trinzic IPAM Insight. Its Trinzic Enterprise product is an appliance that is designed to for continuous operation of network control. Trinzic Enterprise offers file delivery services via the File Transfer Protocol (FTP), Trivial File Transfer Protocol (TFTP), and Hypertext Transfer Protocol (HTTP), time synchronization services via the Network Time Protocol (NTP) and Logging services via Syslog.
Trinzic IPAM for Microsoft provides a single, Web-based management interface for the centralized management of DNS, DHCP and multiple IP address pools running on Microsoft servers without any installation of software on Microsoft servers. It also provides Microsoft server management capabilities, such as centralized IP address management! , DNS changes and individualized, role-based access control. Trinzic Reporting provides long-term reporting, trending, analysis and tracking capabilities to report network utilization, isolate performance problems, implement DHCP and DNS capacity planning and identify security threats. Trinzic Reporting automates tasks associated with collecting, tabulating and correlating data and displays the information through its Web-based management interface. Trinzic IPAM Insight allows automated discovery of network device configuration information used in automation and compliance reporting.
Trinzic NetMRI Family
The Company�� Trinzic NetMRI products components of include Trinzic Network Automation, Trinzic Network Compliance, Trinzic Switch Port Manager and Trinzic PCI Insight. Its Trinzic NetMRI product automates network change and configuration management processes. Trinzic NetMRI enables information technology organizations to automate network changes, gain visibility into the impact of changes occurring on the network, manage network configurations, archive network configurations and meet a range of compliance requirements for both physical and virtual machines. Trinzic NetMRI discovers and monitors network infrastructure devices to determine critical network information. It uses this information to analyze network stability, to identify unauthorized devices and to take inventory of network devices for inventory management and/or troubleshooting. Trinzic Network Automation automates network configuration functions.
Trinzic Network Compliance automates the network compliance process, meeting corporate security requirements and providing the necessary information and control for internal and external compliance mandates. Trinzic Network Compliance also automatically alerts IT personnel in the event of a failure to meet compliance guidelines and permits the establishment and deployment of specific end customer requirements with click and drag simplicity, supporting ! complianc! e mandates such as those under the Payment Card Industry Data Security Standard (PCI DSS), the Health Insurance Portability and Accountability Act of 1996 (HIPAA), the Sarbanes-Oxley Act, Federal Energy Regulatory Commission (FERC) and North American Electric Reliability Corporation (NERC).
Trinzic Switch Port Manager enables its end customers to identify the number of switch ports, manage them precisely and locate the next available switch port. It helps provide views and management of switches with both current and historical IP addresses, MAC addresses, VLAN mappings and network device topology information. It also shows where devices have been connected, when they connected and where they are currently connected so that the network administrator can easily track authorized devices and find rogue devices that can pose security risks and create network instability. Trinzic PCI Insight is an integrated offering that bundles Trinzic Network Compliance, Trinzic IPAM Insight from its Trinzic Enterprise family of products and consulting services and enables its end customers to optimize their PCI DSS compliance.
The Company competes with BMC Software, Inc., EMC Corporation, Hewlett-Packard Company and International Business Machines Corporation, Alcatel-Lucent, BT Group plc and BlueCat Networks, Inc.
Advisors' Opinion:- [By Evan Niu, CFA]
What: Shares of Infoblox (NYSE: BLOX ) have popped today by as much as 18% after the company reported earnings.
So what: Revenue in the fiscal third quarter came in at a record $58 million, topping the Street's $56 million forecast. Non-GAAP earnings per share totaled $0.11, also ahead of the $0.06-per-share adjusted profit that investors were expecting. CEO Robert Thomas said the company's value proposition -- helping networks become more automated and secure -- is driving its outperformance.
- [By John Udovich]
Just before Thanksgiving, small cap networking stock Infoblox Inc (NYSE: BLOX) sank 28.65% on guidance that was below expectations, but the stock has still outperformed the year-to-date�performance of�networking ETF like the PowerShares Dynamic Networking ETF (NYSEARCA: PXQ) and iShares S&P North American Networking ETF (NYSEARCA: IGN). So what went wrong and could investors have just overeacted?
Top 10 Safest Companies To Buy For 2014: Baxter International Inc. (BAX)
Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. It operates in three segments: BioScience, Medication Delivery, and Renal. The BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines. The Medication Delivery segment manufactures intravenous solutions and administration sets; premixed drugs and drug-reconstitution systems; pre-filled vials and syringes for injectable drugs; intravenous nutrition products; infusion pumps; and inhalation anesthetics. It also offers products and services related to pha rmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease or irreversible kidney failure. It manufactures solutions and other products for peritoneal dialysis, a home-based therapy; and distributes product for hemodialysis, which is conducted in a hospital or clinic. It markets its products to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors? offices, clinical and medical research laboratories, and patients at home under physician supervision. The company was founded in 1931 and is based in Deerfield, Illinois.
Advisors' Opinion:- [By Monica Gerson]
Baxter International (NYSE: BAX) is expected to report its Q1 earnings at $1.09 per share on revenue of $3.88 billion.
The Sherwin-Williams Company (NYSE: SHW) is projected to report its Q1 earnings at $1.11 per share on revenue of $2.36 billion.
- [By Jon C. Ogg]
Baxter International Inc. (NYSE: BAX) was downgraded to Neutral from Outperform at Credit Suisse based on earnings uncertainty around its competitive long-acting recombinant franchise.
- [By Seth Jayson]
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Baxter International (NYSE: BAX ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Baxter International doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 1.8%, and inventory increased 8.3%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue grew 1.8%, and inventory increased 8.3%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 8.1%, and inventory grew 5.7%.
Top 10 Safest Companies To Buy For 2014: Colonial Municipal Income Trust (CMU)
MFS High Yield Municipal Trust operates as a nondiversified, closed-end management investment company. The trust invests primarily in medium and lower quality bonds and notes issued by or on behalf of state and local government units. Its portfolio primarily comprises investments in health care, tax-backed, utilities, transportation, housing, education, industrials, resource recovery, industrial, manufacturing, oil and gas, and refunded/escrowed sectors. Columbia Management Advisors, Inc. serves as the investment advisor of the trust. The trust was formerly known as Colonial Municipal Income Trust and changed its name to MFS High Yield Municipal Trust in 2007. MFS High Yield Municipal Trust was founded in 1987 and is based in Boston, Massachusetts.
Advisors' Opinion:- [By Paul McWilliams]
Marvell (MRVL) is clearly carrying a big zit on its forehead from the ongoing legal battle with Carnigie Mellon University (CMU). A jury awarded CMU damages slightly in excess of $1B, and the judge could triple that.
No comments:
Post a Comment